StreetInsider.com News Articles

Form 6-K Valneva SE For: Dec 31

Thu, 15 Oct 2026 10:30:00 -0400

si-local-file:///var/storage/secattach/20261015/27191641.html

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Wed, 14 Oct 2026 11:45:00 -0400

Lyon (France), October 14, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in meetings with institutional investors at upcoming investor conferences in the United States and Europe.

In addition to meeting with investors, Valneva will host moderated “fireside chat” presentations to discuss the Company’s key value drivers and upcoming catalysts, primarily the regulatory outlook for the Company’s Lyme disease vaccine candidate, which is partnered with Pfizer, and for which regulatory decisions are expected within the next 12 months. Valneva

Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences

Wed, 14 Oct 2026 11:45:00 -0400

Form 6-K Valneva SE For: Dec 31

Thu, 08 Oct 2026 07:58:00 -0400

si-local-file:///var/storage/secattach/20261008/27163806.html

Valneva ADRs fall as UK revokes IXCHIQ marketing authorization

Wed, 07 Oct 2026 16:22:48 -0400

Investing.com -- Valneva SE ADRs (NASDAQ:VALN) fell 6.5% in after-hours trading Wednesday after the UK revoked the marketing authorization for its IXCHIQ chikungunya vaccine following a benefit-risk review.

The Medicines and Healthcare products Regulatory Agency (MHRA) revoked the authorization after the UK's Commission on Human Medicines conducted a benefit-risk assessment for travelers. The decision was based on a review of previous safety data and was not associated with any newly identified safety signal, according to the company.

The revocation does not affect product licenses for IXCHIQ in the EU, Canada, Brazil, or other territories where the vaccine is currently marketed.

IXCHIQ was launched

Valneva ADRs fall as UK revokes IXCHIQ marketing authorization

Wed, 07 Oct 2026 16:22:48 -0400

The revocation does not affect product licenses for IXCHIQ in the EU, Canada, Brazil, or other territories where the vaccine is currently marketed.

IXCHIQ was launched

UK revokes Valneva's IXCHIQ marketing authorization after benefit-risk review

Wed, 07 Oct 2026 16:00:47 -0400

The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has revoked the marketing authorization for Valneva SE's (Nasdaq: VALN; Euronext Paris: VLA) chikungunya vaccine IXCHIQ, following a benefit-risk assessment by the Commission on Human Medicines (CHM).

According to a statement from Valneva, the decision was based on a review of existing safety data and was not associated with any newly identified safety signal. The revocation applies only to the UK and does not affect IXCHIQ's product licenses in the European Union, Canada, Brazil, or other markets where the vaccine is currently sold.

IXCHIQ was launched in the UK in mid-2025 but

Valneva Provides Update on IXCHIQ® in the United Kingdom

Wed, 07 Oct 2026 16:00:00 -0400

Lyon (France), October 07, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that, following a further benefit-risk assessment of IXCHIQ^® for travelers by the United Kingdom’s (UK) Commission on Human Medicines (CHM), the UK marketing authorization for IXCHIQ^® has been revoked by the Medicines and Healthcare products Regulatory Agency (MHRA). The decision was based on a review of previous safety data and was not associated with any newly identified safety signal. It does not affect the product licenses for IXCHIQ^® in the EU, Canada, Brazil, or other territories where IXCHIQ^®

Valneva Provides Update on IXCHIQ® in the United Kingdom

Wed, 07 Oct 2026 16:00:00 -0400

Form 6-K Valneva SE For: Dec 31

Fri, 14 Aug 2026 11:27:00 -0400

si-local-file:///var/storage/secattach/20260814/26927234.html

Form 6-K Valneva SE For: Dec 31

Fri, 14 Aug 2026 11:27:00 -0400

si-local-file:///var/storage/secattach/20260814/26927234.html

Form 6-K Valneva SE For: Dec 31

Fri, 14 Aug 2026 11:27:00 -0400

si-local-file:///var/storage/secattach/20260814/26927234.html

Form 6-K Valneva SE For: Jun 30

Thu, 13 Aug 2026 10:28:00 -0400

si-local-file:///var/storage/secattach/20260813/26918190.html

Form 6-K Valneva SE For: Jun 30

Thu, 13 Aug 2026 10:28:00 -0400

si-local-file:///var/storage/secattach/20260813/26918190.html

Form 6-K Valneva SE For: Jun 30

Thu, 13 Aug 2026 10:28:00 -0400

si-local-file:///var/storage/secattach/20260813/26918190.html

TD Cowen Starts Valneva SE (VALN) at Buy

Tue, 11 Aug 2026 02:43:11 -0400

TD Cowen analyst Tara Bancroft initiates coverage on Valneva SE (NASDAQ: VALN) with a Buy rating and a price target of $12.00.

The analyst comments: “Valneva's base vaccine business offers downside protection, while LB6V is a de-risked Lyme disease vaccine supported by validated biology and PFE’s regulatory expertise. We estimate ~€590MM of royalty revenue by 2035 if approved and see meaningful optionality even if PFE does not pursue a filing, including another Ph III study, re-partnering, or potential M&A. Init. at Buy with a $12 DCF-based PT.

LB6V is a multivalent Lyme disease vaccine partnered with PFE with blockbuster potential. It showed

TD Cowen Starts Valneva SE (VALN) at Buy

Tue, 11 Aug 2026 02:43:11 -0400

TD Cowen analyst Tara Bancroft initiates coverage on Valneva SE (NASDAQ: VALN) with a Buy rating and a price target of $12.00.

LB6V is a multivalent Lyme disease vaccine partnered with PFE with blockbuster potential. It showed

Form 6-K Valneva SE For: Dec 31

Wed, 22 Jul 2026 14:22:00 -0400

si-local-file:///var/storage/secattach/20260722/26801006.html

Form 6-K Valneva SE For: Dec 31

Wed, 22 Jul 2026 14:22:00 -0400

si-local-file:///var/storage/secattach/20260722/26801006.html

Form 6-K Valneva SE For: Dec 31

Wed, 22 Jul 2026 14:22:00 -0400

si-local-file:///var/storage/secattach/20260722/26801006.html

Form 6-K Valneva SE For: Dec 31

Thu, 25 Jun 2026 11:57:00 -0400

si-local-file:///var/storage/secattach/20260625/26690396.html

Form 6-K Valneva SE For: Dec 31

Thu, 25 Jun 2026 11:57:00 -0400

si-local-file:///var/storage/secattach/20260625/26690396.html

Form 6-K Valneva SE For: Dec 31

Thu, 25 Jun 2026 11:57:00 -0400

si-local-file:///var/storage/secattach/20260625/26690396.html

Form EFFECT Valneva SE

Wed, 17 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260617/26656416.html

Form EFFECT Valneva SE

Wed, 17 Jun 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260617/26656416.html